Researchers Developed mRNA Vaccines for SFTS Virus
A new study evaluated three vaccine candidates that protected mice from lethal virus challenge.
Updated on Sept. 23, 2026 in Diseases — General
Live Poll
Do you support the early release of medical research before it completes full peer review?
Researchers have successfully developed three lipid nanoparticle-mRNA vaccine candidates to combat severe fever with thrombocytopenia syndrome. The experimental vaccines provided protection against lethal viral challenges in a mouse model study.
Why it matters
Severe fever with thrombocytopenia syndrome currently lacks an approved vaccine and carries a high fatality rate. This research addresses the urgent need for a preventative measure as global outbreaks continue to increase.
The study tested three distinct mRNA vaccine candidates against a virus with a mortality rate ranging from 10% to 27%. While all candidates protected mice from lethal infection, only those encoding Gn and Gc proteins induced neutralizing activity.
The details
The research team utilized lipid nanoparticle-mRNA technology to encode viral proteins Gn, Gc, and NP. While immunization with all three successfully prevented lethal outcomes in Ifnar1 mice, the protective mechanism for the NP-encoded vaccine relied on CD4 cells rather than virus-neutralizing activity.
Timeline
The article detailing the preclinical mRNA vaccine research was published on September 23, 2026.
The Big Picture
This study follows the precedent set by the mRNA platform technology utilized in COVID-19 vaccine development by applying similar lipid nanoparticle methods to a new viral target. By leveraging this established technology, researchers are accelerating the timeline for responding to emerging infectious diseases.
This early-stage research provides a foundation for future human clinical trials that could eventually lead to a preventive vaccine for the public. However, there are currently no available vaccinations or immediate changes to clinical treatment protocols for those at risk.
The takeaway
These findings demonstrate the versatility of mRNA platforms in targeting viruses that have historically lacked effective medical countermeasures. Future research will be essential to determine if these results translate from laboratory mouse models to human applications.
Further reading
For more information on similar medical advancements, visit the Diseases — General section.
Source note: This article includes information reported by Nature.
Live Poll
Do you support the early release of medical research before it completes full peer review?
